Brief: Shanghai Henlius Biotech Posts H1 Revenue Of RMB2,746.1 Mln
26/08/2024 11:41
Aug 26 (Reuters) - Shanghai Henlius Biotech H1 revenue RMB 2,746.1 million. * H1 net income RMB 386.3 million * H1 gross profit RMB 1,990.7 million
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln